Imagen de Portada

Letter: Toward Intra‐Class Switching With JAK Inhibitors?

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathieu Uzzan, David Laharie
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
por: Mathieu Uzzan, et al.
Publicado: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
por: Shintaro Akiyama, et al.
Publicado: (2025)

Letter: Should ulcerative colitis be monitored more or less invasively?
por: David Laharie
Publicado: (2024)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
por: Mathilde Osty, et al.
Publicado: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
por: Nicolas Richard, et al.
Publicado: (2026)

Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study
por: Nathan Grellier, et al.
Publicado: (2024)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
por: Shoko Miyahara, et al.
Publicado: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
por: Kee Huat Chuah, et al.
Publicado: (2025)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
por: Cheng‐Hsien Hung, et al.
Publicado: (2025)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
por: Eiichi Ogawa
Publicado: (2024)

Letter: Gas‐Sensing Capsules Advance Colonic Physiology Research Toward Clinical Translation
por: Anastasios Koulaouzidis, et al.
Publicado: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
por: Qiang Hu, et al.
Publicado: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
por: Tamar Schildkraut, et al.
Publicado: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
por: Yewan Park, et al.
Publicado: (2024)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
por: Jia‐Yong Su, et al.
Publicado: (2025)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
por: Annalisa Schiepatti, et al.
Publicado: (2024)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
por: Isabella Lurje, et al.
Publicado: (2025)

Letter: Irritable bowel syndrome and antibiotics
por: George F. Longstreth
Publicado: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
por: Kacie H. Denton, et al.
Publicado: (2026)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
por: David Bergman, et al.
Publicado: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
por: Yong‐Hai Zhou, et al.
Publicado: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
por: Juntao Lu, et al.
Publicado: (2026)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
por: Jurij Maurer, et al.
Publicado: (2026)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data
por: John David Chetwood, et al.
Publicado: (2024)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
por: Richard Pollok
Publicado: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
por: Fernanda Cristofori, et al.
Publicado: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
por: Ewan Forrest, et al.
Publicado: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
por: Kyle Staller, et al.
Publicado: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
por: Christophe Corpechot
Publicado: (2026)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
por: Mustafa Mohamedrashed, et al.
Publicado: (2024)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
por: David Tornai, et al.
Publicado: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
por: Jiru Li, et al.
Publicado: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
por: Kuan‐Ju Lin, et al.
Publicado: (2025)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
por: Finlay Macrae
Publicado: (2025)

Letter: Identifying the Best Model for Predicting Post‐SVR HCC
por: Hidenori Toyoda
Publicado: (2025)

Letter: TB‐CD Puzzle—Is tNGS the Final Piece?
por: Abhishek Yadav, et al.
Publicado: (2025)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
por: Jiamei Wang, et al.
Publicado: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
por: Mingsi Zhang, et al.
Publicado: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
por: Yaomin Wang, et al.
Publicado: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
por: Muhammad Osama, et al.
Publicado: (2024)